• Novo Nordisk has proposed to acquire Ablynx biospectrumasia
    January 10, 2018
    Novo Nordisk recently announced that it made a proposal on 22 December 2017 to acquire Ablynx for EUR 28.00 per share in cash and one CVR with total potential cash payments over time of up to EUR 2.50 per share.
PharmaSources Customer Service